# To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

> **NCT04551066** · PHASE3 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 252 (actual)

## Conditions studied

- Myelofibrosis
- Primary Myelofibrosis
- Post Essential Thrombocythemia Myelofibrosis
- Post Polycythemia Vera Myelofibrosis

## Interventions

- **DRUG:** parsaclisib
- **DRUG:** ruxolitinib
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04551066
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-24
- **Primary completion:** 2023-08-03
- **Final completion:** 2024-11-25
- **Target enrollment:** 252 (ACTUAL)
- **Why stopped:** The study was terminated due to futility.
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551066, "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04551066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*